MCID: TCL028
MIFTS: 47

T-Cell Lymphoblastic Leukemia/lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for T-Cell Lymphoblastic Leukemia/lymphoma

MalaCards integrated aliases for T-Cell Lymphoblastic Leukemia/lymphoma:

Name: T-Cell Lymphoblastic Leukemia/lymphoma 12 15
T-Cell Leukemia 12 17
Leukemia, T-Cell 43
Leukemia T-Cell 54

Classifications:



External Ids:

Disease Ontology 12 DOID:715
MeSH 43 D015458
UMLS 71 C0023492

Summaries for T-Cell Lymphoblastic Leukemia/lymphoma

MalaCards based summary : T-Cell Lymphoblastic Leukemia/lymphoma, also known as t-cell leukemia, is related to adult t-cell leukemia and human t-cell leukemia virus type 2. An important gene associated with T-Cell Lymphoblastic Leukemia/lymphoma is MIR106A (MicroRNA 106a), and among its related pathways/superpathways are PI3K-Akt signaling pathway and NF-kappaB Signaling. The drugs Zidovudine and Peginterferon alfa-2b have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and bone.

Related Diseases for T-Cell Lymphoblastic Leukemia/lymphoma

Diseases related to T-Cell Lymphoblastic Leukemia/lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 565)
# Related Disease Score Top Affiliating Genes
1 adult t-cell leukemia 35.6 IL2RA IL2 CNTN2
2 human t-cell leukemia virus type 2 35.1 CREB1 CNTN2
3 human t-cell leukemia virus type 1 34.7 CREB1 CNTN2
4 precursor t-cell acute lymphoblastic leukemia 34.3 TLX1 TCL1A TAL1 NOTCH1 LMO2
5 leukemia, acute lymphoblastic 34.2 TLX1 TAL1 NOTCH1 MIR130B LMO2 IL2
6 t-cell acute lymphoblastic leukemia 34.2 TLX1 TAL1 NOTCH1 LMO2 LCK IL2RA
7 tropical spastic paraparesis 33.8 IL2RA IL2 CNTN2
8 leukemia, chronic lymphocytic 32.3 TCL1B TCL1A NOTCH1 MIR143 LCK IL2RA
9 severe combined immunodeficiency 32.3 NOTCH1 LMO2 LCK IL2RA IL2 CREB1
10 leukemia 32.1 TLX1 TCL1B TCL1A TAL1 NOTCH1 LMO2
11 lymphoma 32.1 TLX1 TCL1B TCL1A TAL1 NOTCH1 IL2RA
12 lymphoma, non-hodgkin, familial 31.9 TCL1A TAL1 NOTCH1 MIR143 LCK IL2RA
13 prolymphocytic leukemia 31.9 TCL1A IL2RA ADA
14 lymphoblastic lymphoma 31.7 TLX1 TAL1 NOTCH1 LMO2
15 leukemia, acute myeloid 31.7 TAL1 NOTCH1 MIR130B LMO2 LCK IL2
16 hairy cell leukemia 31.6 IL2RA IL2 ADA
17 peripheral t-cell lymphoma 31.6 TCL1A NOTCH1 IL2
18 diffuse large b-cell lymphoma 31.6 TCL1A MIR143 MIR106A LMO2 CCND3
19 lymphopenia 31.5 LCK IL2RA IL2 ADA
20 hematologic cancer 31.3 NOTCH1 MIR143 MIR130B MIR106A IL2RA IL2
21 t-cell large granular lymphocyte leukemia 31.3 IL2RA IL2 CNTN2
22 t-cell adult acute lymphocytic leukemia 31.3 IL2 CREB1 CNTN2
23 mantle cell lymphoma 31.3 TCL1A NOTCH1 GAS5 CCND3
24 pulmonary tuberculosis 31.2 IL2RA IL2 ADA
25 lung cancer susceptibility 3 30.8 NOTCH1 MIR20B MIR143 MIR130B GAS5 CREB1
26 red cell aplasia 30.5 IL2RA IL2
27 pediatric t-cell leukemia 12.6
28 human t-cell leukemia virus type 3 12.6
29 n syndrome 12.0
30 htlv-1 associated myelopathy/tropical spastic paraparesis 11.9
31 t-cell prolymphocytic leukemia 11.8
32 myelopathy, htlv-1-associated 11.8
33 glut1 deficiency syndrome 1 11.3
34 retrovirus-associated myelopathy 11.3
35 follicular lymphoma 11.2
36 agammaglobulinemia 11.1
37 hepatosplenic t-cell lymphoma 11.1
38 spastic paraparesis 11.0
39 chronic interstitial cystitis 10.9
40 alcoholic hepatitis 10.8
41 combined t cell and b cell immunodeficiency 10.8 NOTCH1 LMO2 LCK IL2RA IL2 ADA
42 severe combined immunodeficiency, x-linked 10.8 LMO2 IL2RA IL2 ADA
43 splenic diffuse red pulp small b-cell lymphoma 10.8 NOTCH1 CCND3
44 human immunodeficiency virus type 1 10.7
45 splenic manifestation of leukemia 10.7 TCL1B TCL1A
46 immune system disease 10.7 MIR20B MIR143 MIR106A IL2
47 breast liposarcoma 10.7 NOTCH1 IL2
48 bile duct adenocarcinoma 10.7 NOTCH1 MIR20B MIR106A
49 common variable immunodeficiency 10.7 LCK IL2RA IL2 ADA
50 mycosis fungoides 10.7

Graphical network of the top 20 diseases related to T-Cell Lymphoblastic Leukemia/lymphoma:



Diseases related to T-Cell Lymphoblastic Leukemia/lymphoma

Symptoms & Phenotypes for T-Cell Lymphoblastic Leukemia/lymphoma

Drugs & Therapeutics for T-Cell Lymphoblastic Leukemia/lymphoma

Drugs for T-Cell Lymphoblastic Leukemia/lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 339)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zidovudine Approved Phase 4 30516-87-1 35370
2
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
3
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
4 Interferon alpha-2 Phase 4
5 Interferon-alpha Phase 4
6 Anti-HIV Agents Phase 4
7 interferons Phase 4
8 Reverse Transcriptase Inhibitors Phase 4
9 Anti-Retroviral Agents Phase 4
10 Anticonvulsants Phase 4
11
Vindesine Approved, Investigational Phase 3 59917-39-4, 53643-48-4 40839
12
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
13
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
14
Clavulanate Approved, Vet_approved Phase 3 58001-44-8 5280980
15
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
16
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
17
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
18 Orange Approved Phase 3
19
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
20
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 27284 23925
21
Dalteparin Approved Phase 3 9005-49-6
22
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
23
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
24
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
25
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
26
Ofloxacin Approved Phase 3 82419-36-1 4583
27
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
28
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
29
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
30
Tazobactam Approved Phase 3 89786-04-9 123630
31
Vancomycin Approved Phase 3 1404-90-6 14969 441141
32
Piperacillin Approved Phase 3 66258-76-2 43672
33
Idarubicin Approved Phase 2, Phase 3 58957-92-9 42890
34
Azathioprine Approved Phase 3 446-86-6 2265
35
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
36
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
37
Pegaspargase Approved, Investigational Phase 3 130167-69-0
38
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
39
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
40
Mercaptopurine Approved Phase 3 50-44-2 667490
41
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
42
Daunorubicin Approved Phase 3 20830-81-3 30323
43
Ifosfamide Approved Phase 3 3778-73-2 3690
44
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
45
Thioguanine Approved Phase 3 154-42-7 2723601
46
Ichthammol Approved Phase 3 8029-68-3
47
Vincristine Approved, Investigational Phase 2, Phase 3 57-22-7, 2068-78-2 5978
48
Prednisone Approved, Vet_approved Phase 2, Phase 3 53-03-2 5865
49
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
50
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462

Interventional clinical trials:

(show top 50) (show all 413)
# Name Status NCT ID Phase Drugs
1 HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL) Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) Completed NCT01418430 Phase 4 CHOP-daclizumab
2 HTLV Blot 2.4 Post-Market Clinical Study of Neurological Disorders and HTLV Positive Specimens Completed NCT03226119 Phase 4
3 Prospective Study of the Molecular Characteristics of Sensitive and Resistant Disease in Patients With HTLV-I Associated Adult T Cell Leukemia Treated With Zidovudine (AZT) Plus Interferon Alpha-2b Terminated NCT00854581 Phase 4 Valproic Acid;Zidovudine
4 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
5 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
6 The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenance in Acute Lymphoblastic Leukemia and Lymphoblastic Non-Hodgkin Lymphoma of Childhood Unknown status NCT00003728 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisolone;therapeutic hydrocortisone;thioguanine;vincristine sulfate;vindesine
7 Randomised Study Comparing 6 And 8 Cycles Of Chemotherapy With CHOP ( Cyclophosphamide, Doxorubicin, Vincristine And Prednisone) At 14-Day Intervals (CHOP-14), Both With Or Without The Monoclonal Anti-CD20 Antibody Rituximab In Patients Aged 61 To 80 Years With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
8 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
9 Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients Unknown status NCT03023358 Phase 3 chidamide;cyclophosphamide;liposomal doxorubicin;vincristine;prednisone
10 Phase III Study of VCAP-AMP-VECP vs. Biweekly CHOP in Aggressive Adult T-cell Leukemia-lymphoma (ATLL): Japan Clinical Oncology Group Study, JCOG9801. Completed NCT00145002 Phase 3 VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis;biweekly-CHOP with G-CSF and intrathecal prophylaxis
11 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
12 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
13 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
14 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
15 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
16 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
17 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
18 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
19 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
20 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
21 Intensive Treatment For T-CELL Acute Lymphoblastic Leukemia and Advanced Stage Lymphoblastic Non-Hodgkin's Lymphoma: A Pediatric Oncology Group Phase III Study Completed NCT01230983 Phase 3 asparaginase;cytarabine;dexrazoxane hydrochloride;doxorubicin hydrochloride;leucovorin calcium;mercaptopurine;methotrexate;prednisone;therapeutic hydrocortisone;vincristine sulfate
22 ALLR3: An International Collaborative Trial for Relapsed and Refractory Acute Lymphoblastic Leukaemia (ALL) Completed NCT00967057 Phase 3 asparaginase;dexamethasone;idarubicin;methotrexate;mitoxantrone hydrochloride;pegaspargase;vincristine sulfate
23 A Multicenter Study of Treatment Protocol for Childhood Acute Lymphoblastic Leukemia in China, 2008. Completed NCT00707083 Phase 3 dexamethasone;mercaptopurine;methotrexate;vincristine sulfate
24 Treatment of Acute Lymphoblastic Leukemia in Children Completed NCT00400946 Phase 3 asparaginase;cyclophosphamide;cytarabine;dexamethasone;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;pegaspargase;prednisolone;therapeutic hydrocortisone;vincristine sulfate
25 A Randomized, Prospective Double-Blind, Placebo-Controlled Trial of Prophylactic Oral Levofloxacin Following Chemotherapy for Lymphoma and Solid Tumors Completed NCT00005590 Phase 3 levofloxacin
26 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
27 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
28 Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
29 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
30 An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Total Therapy for Adult T-lymphoblastic Lymphoma/Leukemia Recruiting NCT03564704 Phase 2, Phase 3 Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-mercaptopurine.;Etoposide;Cytarabine;Chidamide
31 An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Target Total Therapy for Adult Early T-cell Progenitor Acute Lymphoblastic Leukemia/Lymphoma Recruiting NCT03553238 Phase 2, Phase 3 Chidamide;Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-Mercaptopurine;Etoposide;Cytarabine
32 A Randomized Trial for Adults With Newly Diagnosed Acute Lymphoblastic Leukemia Recruiting NCT01085617 Phase 3 cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;imatinib mesylate;melphalan;mercaptopurine;methotrexate;nelarabine;pegaspargase;vincristine sulfate
33 International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones Recruiting NCT03007147 Phase 3 Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Dexrazoxane Hydrochloride;Doxorubicin;Etoposide;Ifosfamide;Imatinib Mesylate;Leucovorin Calcium;Mercaptopurine;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Prednisolone;Therapeutic Hydrocortisone;Thioguanine;Vincristine Sulfate
34 A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807) Active, not recruiting NCT00557193 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Etoposide;Lestaurtinib;Leucovorin Calcium;Mercaptopurine;Methotrexate;Methylprednisolone;Pegaspargase;Prednisone;Therapeutic Hydrocortisone;Vincristine Sulfate
35 A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy) Active, not recruiting NCT02112916 Phase 3 Bortezomib;Cyclophosphamide;Cytarabine;Daunorubicin;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin;Doxorubicin Hydrochloride;Etoposide;Hydrocortisone Sodium Succinate;Ifosfamide;Leucovorin Calcium;Mercaptopurine;Methotrexate;Pegaspargase;Thioguanine;Vincristine;Vincristine Sulfate
36 Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma Active, not recruiting NCT00408005 Phase 3 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin Hydrochloride;Dexamethasone;Doxorubicin Hydrochloride;Leucovorin Calcium;Mercaptopurine;Methotrexate;Nelarabine;Pegaspargase;Prednisone;Thioguanine;Vincristine Sulfate
37 Diffuse Large B Cell And Peripheral T Cell Non-Hodgkin's Lymphomas (NHL) In The Elderly. Influence Of Prolonged Oral Etoposide Added To CHOP Combination Chemotherapy In Patients With Good Physiological Status. An EORTC Randomized Phase II-III Trial Including Geriatric Assessment And Quality Of Life Terminated NCT00060385 Phase 2, Phase 3 CHOP regimen;EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate
38 CELTIC-1 (Clinical Evaluation of T-cell NHL With Cerdulatinib): A Phase 2b, Open Label, Multidose, Multinational Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Withdrawn NCT04021082 Phase 2, Phase 3 Cerdulatinib
39 Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
40 DFCI ALL Adult Consortium Protocol: Adult ALL Trial Unknown status NCT01005758 Phase 2 cyclophosphamide;cytarabine;dexamethasone;doxorubicin hydrochloride;etoposide phosphate;hydrocortisone sodium succinate;imatinib mesylate;mercaptopurine;methotrexate;methylprednisolone;pegaspargase;prednisolone;prednisone;vincristine sulfate
41 MULTICENTRE TRIAL OF INTENSIFIED THERAPY FOR ADULT ALL (O5/93) Unknown status NCT00002531 Phase 2 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;ifosfamide;leucovorin calcium;mercaptopurine;methotrexate;mitoxantrone hydrochloride;prednisolone;teniposide;thioguanine;vincristine sulfate;vindesine
42 A Phase II Evaluation of High Dose Chemotherapy and Autologous Stem Cell Transplantation for Intestinal T-cell Lymphomas Unknown status NCT00669812 Phase 2 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;epirubicin hydrochloride;etoposide;ifosfamide;melphalan;methotrexate;prednisolone;vincristine sulfate
43 Alemtuzumab and CHOP Chemotherapy for Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Centre Phase I and II Study Unknown status NCT00363090 Phase 1, Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
44 Non-Ablative Chemotherapeutic Conditioning Before Allogeneic Stem Cell Transplantation Unknown status NCT00008307 Phase 2 cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil
45 Phase II Study of Arsenic Trioxide in Relapsed/Refractory Acute Leukemia and Blast Crisis of Chronic Myeloid Leukemia Unknown status NCT00003885 Phase 2 arsenic trioxide
46 Allograft of Hematopoietic Stem Cells With Reduced-intensity Conditioning From a HLA-haploidentical Family Donor: Phase II Study of Combined Immunosuppression Before and After Transplantation Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
47 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
48 Randomised Placebo Controlled Trial of Faecal Microbiota Transplantation in Irritable Bowel Syndrome Unknown status NCT02423421 Phase 2
49 A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma Completed NCT01724177 Phase 2 Lenalidomide
50 Phase II Clinical Study of KW-0761 in Patients With CCR4-Positive Adult T-cell Leukemia-Lymphoma Completed NCT00920790 Phase 2

Search NIH Clinical Center for T-Cell Lymphoblastic Leukemia/lymphoma

Cochrane evidence based reviews: leukemia, t-cell

Genetic Tests for T-Cell Lymphoblastic Leukemia/lymphoma

Anatomical Context for T-Cell Lymphoblastic Leukemia/lymphoma

MalaCards organs/tissues related to T-Cell Lymphoblastic Leukemia/lymphoma:

40
T Cells, B Cells, Bone, Bone Marrow, Skin, Myeloid, Liver

Publications for T-Cell Lymphoblastic Leukemia/lymphoma

Articles related to T-Cell Lymphoblastic Leukemia/lymphoma:

(show top 50) (show all 8795)
# Title Authors PMID Year
1
Role of microRNA-143 in Fas-mediated apoptosis in human T-cell leukemia Jurkat cells. 61 46
19464056 2009
2
Roles for microRNAs, miR-93 and miR-130b, and tumor protein 53-induced nuclear protein 1 tumor suppressor in cell growth dysregulation by human T-cell lymphotrophic virus 1. 61 46
18974142 2008
3
Oncogenic potential of the miR-106-363 cluster and its implication in human T-cell leukemia. 61 46
17575136 2007
4
Transactivation of human osteopontin promoter by human T-cell leukemia virus type 1-encoded Tax protein. 54 61
19767100 2010
5
Cyclic AMP response element-binding protein is implicated in IL-6 production from arthritic synovial cells. 54 61
19921094 2010
6
Molecular approach to human leukemia: isolation and characterization of the first human retrovirus HTLV-1 and its impact on tumorigenesis in adult T-cell leukemia. 61 54
20154469 2010
7
Tax unleashed: fulminant Tax-positive Adult T-cell Leukemia/Lymphoma after failed allogeneic stem cell transplantation. 61 54
19836302 2009
8
Inhibition of the hTERT promoter by the proto-oncogenic protein TAL1. 54 61
19587703 2009
9
Transcriptional activation of the interleukin-21 gene and its receptor gene by human T-cell leukemia virus type 1 Tax in human T-cells. 54 61
19617351 2009
10
Enhancement of TRAIL cytotoxicity by AG-490 in human ALL cells is characterized by downregulation of cIAP-1 and cIAP-2 through inhibition of Jak2/Stat3. 61 54
19564891 2009
11
Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions. 54 61
19561642 2009
12
Targeting LMO2 with a peptide aptamer establishes a necessary function in overt T-cell neoplasia. 61 54
19487290 2009
13
Localization of CD26/DPPIV in nucleus and its nuclear translocation enhanced by anti-CD26 monoclonal antibody with anti-tumor effect. 54 61
19555512 2009
14
Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy. 54 61
19461887 2009
15
Double minute chromosomes containing MYB gene and NUP214-ABL1 fusion gene in T-cell leukemia detected by single nucleotide polymorphism DNA microarray and fluorescence in situ hybridization. 54 61
18799215 2009
16
Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas. 54 61
19147787 2009
17
Acetylation of the human T-cell leukemia virus type 1 Tax oncoprotein by p300 promotes activation of the NF-kappaB pathway. 54 61
19200568 2009
18
HTLV-1 Tax is a critical lipid raft modulator that hijacks IkappaB kinases to the microdomains for persistent activation of NF-kappaB. 61 54
19129196 2009
19
Rev and Rex proteins of human complex retroviruses function with the MMTV Rem-responsive element. 54 61
19192308 2009
20
T cell leukemia/lymphoma 1 and galectin-1 regulate survival/cell death pathways in human naive and IgM+ memory B cells through altering balances in Bcl-2 family proteins. 61 54
19155496 2009
21
Involvement of raft aggregates enriched in Fas/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells. 61 54
19352436 2009
22
The proto-oncogene Bcl3, induced by Tax, represses Tax-mediated transcription via p300 displacement from the human T-cell leukemia virus type 1 promoter. 61 54
18815299 2008
23
Ikaros regulates Notch target gene expression in developing thymocytes. 54 61
18941217 2008
24
(-)-Epigallocatechin gallate regulates CD3-mediated T cell receptor signaling in leukemia through the inhibition of ZAP-70 kinase. 54 61
18687687 2008
25
Foxp3 expression on normal and leukemic CD4+CD25+ T cells implicated in human T-cell leukemia virus type-1 is inconsistent with Treg cells. 54 61
18510697 2008
26
Human T-cell leukemia virus type 1 Tax modulates interferon-alpha signal transduction through competitive usage of the coactivator CBP/p300. 54 61
18678383 2008
27
An interaction between the human T cell leukemia virus type 1 basic leucine zipper factor (HBZ) and the KIX domain of p300/CBP contributes to the down-regulation of tax-dependent viral transcription by HBZ. 54 61
18599479 2008
28
Role of human T-cell leukemia virus type I Tax in expression of the human telomerase reverse transcriptase (hTERT) gene in human T-cells. 61 54
18422743 2008
29
In vitro activation of the IkappaB kinase complex by human T-cell leukemia virus type-1 Tax. 61 54
18223255 2008
30
The E3 ligase Itch negatively regulates inflammatory signaling pathways by controlling the function of the ubiquitin-editing enzyme A20. 54 61
18246070 2008
31
The MDS1-EVI1 gene complex as a retrovirus integration site: impact on behavior of hematopoietic cells and implications for gene therapy. 61 54
18227842 2008
32
The human T-cell leukemia virus type 1 tax protein confers CBP/p300 recruitment and transcriptional activation properties to phosphorylated CREB. 61 54
18070920 2008
33
Evaluation and validation of housekeeping genes in response to ionizing radiation and chemical exposure for normalizing RNA expression in real-time PCR. 61 54
17904413 2008
34
Tax-inducible production of CC chemokine ligand 22 by human T cell leukemia virus type 1 (HTLV-1)-infected T cells promotes preferential transmission of HTLV-1 to CCR4-expressing CD4+ T cells. 54 61
18178833 2008
35
Regulation of telomerase and telomeres: human tumor viruses take control. 61 54
18182620 2008
36
The TCL1 oncoprotein inhibits activation-induced cell death by impairing PKCtheta and ERK pathways. 61 54
17846228 2007
37
Activation of the human T-cell leukemia virus type 1 long terminal repeat by the ternary complex factor Elk-1. 61 54
17898074 2007
38
Decontamination of leukemic cells and enrichment of germ cells from testicular samples from rats with Roser's T-cell leukemia by flow cytometric sorting. 61 54
18042634 2007
39
Targeting autophagic regulation of NFkappaB in HTLV-I transformed cells by geldanamycin: implications for therapeutic interventions. 61 54
17671417 2007
40
Cooperation of NF-kappaB2/p100 activation and the PDZ domain binding motif signal in human T-cell leukemia virus type 1 (HTLV-1) Tax1 but not HTLV-2 Tax2 is crucial for interleukin-2-independent growth transformation of a T-cell line. 54 61
17715223 2007
41
Notch and Ikaros: not only converging players in T cell leukemia. 54 61
18032925 2007
42
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. 61 54
17873882 2007
43
Neurotropin demonstrates cytoprotective effects in lung cells through the induction of thioredoxin-1. 54 61
17585112 2007
44
Lipid raft-mediated uptake of cysteine-modified thioredoxin-1: apoptosis enhancement by inhibiting the endogenous thioredoxin-1. 61 54
17627472 2007
45
Lipoxygenase inhibitors induce death receptor 5/TRAIL-R2 expression and sensitize malignant tumor cells to TRAIL-induced apoptosis. 61 54
17645780 2007
46
Negative regulation of the SH2-homology containing protein-tyrosine phosphatase-1 (SHP-1) P2 promoter by the HTLV-1 Tax oncoprotein. 61 54
17540846 2007
47
BCL3 acts as a negative regulator of transcription from the human T-cell leukemia virus type 1 long terminal repeat through interactions with TORC3. 54 61
17644518 2007
48
Human T-cell leukemia virus type 1 (HTLV-1) p12I down-modulates ICAM-1 and -2 and reduces adherence of natural killer cells, thereby protecting HTLV-1-infected primary CD4+ T cells from autologous natural killer cell-mediated cytotoxicity despite the reduction of major histocompatibility complex class I molecules on infected cells. 61 54
17609265 2007
49
Modulation of dendritic cell maturation and function by the Tax protein of human T cell leukemia virus type 1. 54 61
17442856 2007
50
Enhanced replication of human T-cell leukemia virus type 1 in T cells from transgenic rats expressing human CRM1 that is regulated in a natural manner. 54 61
17360758 2007

Variations for T-Cell Lymphoblastic Leukemia/lymphoma

Expression for T-Cell Lymphoblastic Leukemia/lymphoma

Search GEO for disease gene expression data for T-Cell Lymphoblastic Leukemia/lymphoma.

Pathways for T-Cell Lymphoblastic Leukemia/lymphoma

Pathways related to T-Cell Lymphoblastic Leukemia/lymphoma according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.33 TCL1B TCL1A NOTCH1 IL2RA IL2 CREB1
2 12.31 TAL1 LCK IL2RA IL2
3 12.23 NOTCH1 MIR92A2 MIR19B2 MIR143
4 12 LCK IL2RA IL2 CREB1 CCND3
5 11.72 NOTCH1 IL2RA IL2
6
Show member pathways
11.69 LCK IL2RA IL2
7 11.38 MIR92A2 MIR20B MIR19B2 MIR106A
8 11.21 NOTCH1 IL2RA IL2
9 11.02 LCK IL2RA IL2
10
Show member pathways
10.9 LCK IL2RA IL2
11
Show member pathways
10.75 LCK IL2RA IL2 CCND3

GO Terms for T-Cell Lymphoblastic Leukemia/lymphoma

Cellular components related to T-Cell Lymphoblastic Leukemia/lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 MIR92A2 MIR20B MIR19B2 MIR143 MIR130B MIR106A
2 extracellular vesicle GO:1903561 8.92 MIR92A2 MIR20B MIR19B2 MIR106A

Biological processes related to T-Cell Lymphoblastic Leukemia/lymphoma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.8 NOTCH1 MIR92A2 MIR19B2 CREB1
2 gene silencing by miRNA GO:0035195 9.73 MIR92A2 MIR20B MIR19B2 MIR143 MIR130B MIR106A
3 regulation of cell proliferation GO:0042127 9.67 TAL1 NOTCH1 LCK CCND3
4 miRNA mediated inhibition of translation GO:0035278 9.63 MIR92A2 MIR19B2 MIR106A
5 regulation of regulatory T cell differentiation GO:0045589 9.48 IL2RA IL2
6 negative regulation of inflammatory response GO:0050728 9.46 MIR92A2 IL2RA IL2 ADA
7 positive regulation of T cell receptor signaling pathway GO:0050862 9.43 LCK ADA
8 interleukin-2-mediated signaling pathway GO:0038110 9.4 IL2RA IL2
9 negative regulation of lymphocyte proliferation GO:0050672 9.32 IL2RA IL2
10 regulation of T cell homeostatic proliferation GO:0046013 8.96 IL2RA IL2
11 positive regulation of T cell differentiation GO:0045582 8.8 IL2RA IL2 ADA

Molecular functions related to T-Cell Lymphoblastic Leukemia/lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.1 MIR92A2 MIR20B MIR19B2 MIR143 MIR130B MIR106A

Sources for T-Cell Lymphoblastic Leukemia/lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....